Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

1,014 resultsPage 67 of 85, newest first
  1. FinanceDeepening Implementation of Technological Innovation, Accelerating Transformation of Productive ForcesLegend Holdings Corporation (“Legend Holdings” or the “Company”; Stock Code: 3396.HK) announced the unaudited condensed consolidated interim results for the six months ended June 30, 2026 (the “Reporting Period”). During the Reporting Period, the Company recorded revenue of RMB362.935 billion, representing a 29% year-on-year increase, primarily driven by the significant revenue growth of its subsidiaries Lenovo and Levima Advanced Materials; net profit attributable to equity holders of the Company was RMB2.230 billion, up 219% year-on-year, driven by the recovery in portfolio value of the industrial incubations and investments segment. Excluding the impact of a one-off item, net profit attributable to equity holders of Legend Holdings was RMB5.812 billion, a year-on-year increase of 834%. In the first half of 2026, Legend Holdings remained committed to technological innovation as the key driver for high-quality development and continued to enhance its distinctive technological innovation system. The Company actively drove the coordinated advancement of “anchoring diversified-industries operations in technology-focused core businesses, extending ecosystem coverage through technology innovation funds, and driving the very early-stage industrialization of forward-looking technologies.” This expedited the transformation from scientific and technological achievements into real productive forces, and drove a steady improvement in the Company's core competitiveness, with significant performance growth, laying a solid foundation for the Company’s sustainable development. RMB 10 Billion in R&D Investment, Together with a Solidified Technology Foundation During the Reporting Period, Legend Holdings’ total R&D investment exceeded RMB10 billion, a historical record high for its midyear report. Its portfolio companies continued to deliver steady growth with solid fundamentals. Lenovo capitalized on the surge in hybrid AI, with all three major business segments delivering double-digit revenue growth and reaching record highs for the same period. AI has become Lenovo’s core growth engine, with AI-related revenue increasing by 64% for the same period and accounted for 36% of Lenovo’s total revenue. Levima Advanced Materials posted significant performance growth and made breakthroughs in a number of major projects. Among them, the m-Xylylene Diisocyanate (XDI) project was listed under the National Key R&D Program. Built on Levima’s technical expertise and R&D experience, the PEEK project has entered the construction phase. Both projects are expected to be completed and put into operation in 2027, filling domestic technology gaps. Technology Ecosystem Bearing Fruit, and 12 Portfolio Companies Successfully Listed Leveraging years of dedicated efforts in technology innovation, Legend Holdings has cultivated a robust ecosystem spanning emerging and future industries. This ecosystem is now delivering tangible returns, not only driving significant performance growth for the Company, but also accumulating momentum for long-term development. During the Reporting Period, the industrial incubations and investments segment’s depth of technology asset pipeline and ability to realize value from these assets both improved. In the first half of 2026, the Legend Holdings Family Group supported the listing of 12 portfolio companies. These listed companies spanned sectors including artificial intelligence, semiconductors, advanced manufacturing, and healthcare. More than 30 additional portfolio companies are currently in the pre-listing pipeline. The Company invested in over 80 technology projects in the first half of the year across frontier fields such as artificial intelligence, quantum computing, optical interconnects, embodied artificial intelligence, chips and semiconductors, biopharmaceuticals, and commercial aerospace. To date, Legend Holdings has invested in over 300 AI-related companies. The Company has also established a systematic presence in other frontier fields, having invested in over 110 companies in pharmaceuticals and healthcare, over 60 companies in sustainable industries and future energy, and more than 50 companies in embodied artificial intelligence. Fostering Industry-Academia-Research Collaborative Innovation and Exploring New Pathways for Commercializing Original Technologies Responding to the call to “accelerate the translation from technological advances into productive forces”, Legend Holdings leverages its Forward-Looking Technology Research Institute to actively promote industry-academia-research collaborative innovation and explore new pathways for the commercialization of pioneering technologies. In the first half of the year, Legend Holdings established the Advanced Photonic Integration Joint Laboratory with a National Key Laboratory at Peking University. Together with the research team, the Company published co-authored papers and filed joint patents, while making preparations to establish a dedicated operating entity. In addition, led by the Chinese Information Processing Society of China (CIPS), and jointly initiated by Legend Holdings and other organizations, the Industry University Research Working Committee of the Chinese Information Processing Society of China was established, focusing on frontier areas of artificial intelligence. The Committee translates real-world industry needs into concrete workstreams. The Company has built a “Covalent Innovation” model that brings real-world industry needs into the earliest stages of R&D, enabling businesses and researchers to jointly set priorities and develop solutions. It aims to create a replicable pathway for translating more creative innovation into new quality productive forces. ESG Practices Gaining Authoritative Recognition, Corporate Responsibility Underpinning the Foundation for Sustainability Legend Holdings prioritizes ecological conservation and green development. Lenovo has repeatedly received authoritative recognition both domestically and internationally in the ESG field. It has retained the highest global 3A rating in the MSCI ESG Ratings and received the EcoVadis Platinum Medal, its highest distinction, for two consecutive years. It was also included in the Fortune China ESG Impact List for five consecutive years. Its green operations continued to deliver strong results: over 90% of the electricity used in Lenovo’s global operations came from renewable energy sources. More than 360 million kilograms of end-of-life products have been recovered and reused. In photovoltaic materials, Levima Advanced Materials operates two major product lines for photovoltaic adhesive film materials, EVA and POE, with an annual production capacity exceeding 350,000 tons. In new energy battery materials, the company has built a comprehensive portfolio. In green investment, Legend Holdings has invested in more than 60 companies across new energy, energy decarbonization and so on. The Legend Star CEO Training Program has been running for over 18 years, nurturing up to 1,429 startup founders with 77 listed companies, 217 national-level specialized and innovative “Little Giant” enterprises, 930 High-and New-Technology Enterprises (HNTE), and more than 460,000 jobs created. Looking ahead, Legend Holdings will continue to closely align with national strategic needs, adhere to the main thread of technological innovation driving high-quality development, steadily improve its distinctive technological innovation system, deepen its focus on technology as its core business, and accelerate the promotion of the transformation of scientific achievements into real productive forces, making unremitting contributions to Chinese modernization and self-reliance and strength in science and technology.
  2. FinanceAnalogue Announces 2026 Interim ResultsAnalogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its interim results for the six months ended 30 June 2026 (the “Period”) with interim contracts-in-hand continuing their record-setting performance, providing a solid foundation for the business over the next three years and beyond. Business Highlights - Interim contracts-in-hand surged by 34.9% to HK$17,649.3 million, attaining yet another record high - Revenue was HK$3,036.6 million, up by 5.7%, primarily driven by steady project execution in the Building Services and Environmental Engineering segments - Profit attributable to owners of the Company increased 88.1% to HK$152.0 million. The increase was partly attributable to the disposal of an approximately 3% equity stake in Nanjing Canatal Data-Centre Environmental Tech Co., Ltd.(Shanghai Stock Code: 603912) - The Group maintained a strong cash position, with bank balances and cash at HK$1,214.1 million - Interim dividend amounted to HK4.9 cents per share, with a year-on-year increase of more than 88% - Artificial Intelligence (AI) has been integrated into Analogue’s interconnected smart ecosystem to create value for customers, by realising a smart platform for buildings, and advanced operational solutions for water and sewage treatment, as evidenced by the prestigious accolades across both the research and adoption categories at the inaugural Construction Industry Council AI Award 2026 and at the ASHRAE Region XIII Technology Award 2026 Chairman Dr Mak Kin Wah said, “Building on our outstanding achievement of record-high contracts-in-hand in 2025, the Group maintained steady business performance in the first half of 2026. By integrating research, development and application of AI technologies, we have achieved optimised operations and enhanced quality that earn wide recognition from the industry. Committed to innovation, the Group will further promote integration of AI, Digital Twin, and the Internet of Things (“IoT”), develop cross-technology integrated solutions, and enhance performance in engineering operations, safety, and sustainable development, to create greater value for clients.” “Our commitment to business ethics, quality, safety, health and environmental sustainability remains at the core of everything we do, guiding our decisions, shaping our culture, and contributing to a more sustainable future." Business Review: Building Services - This segment remains the largest revenue contributor, with revenue reaching HK$1,649.6 million. - Interim contracts-in-hand reached a record-high level of HK$7,996.6 million, with order intake standing at HK$1,348.8 million and many of the tenders submitted in the Period due for determination in phases later this year. - Many projects in the Northern Metropolis, including Fanling and Kwu Tung housing projects and various hospitals, were prioritised for commencement and progress in execution. - The Group’s expertise in Building Information Modelling (BIM), Design for Manufacture and Assembly (DfMA) and Modular Integrated Mechanical, Electrical and Plumbing (MiMEP) continued to gain market traction and helped secure major contracts. - Leveraging our comprehensive interdisciplinary capacity and new engineering techniques, this segment maintained our industry leadership, and was broadening our market reach to different parts of Asia. Environmental Engineering - This segment achieved record-high interim contracts-in-hand, which surged substantially by 78.3% year-on-year to HK$8,164.2 million. Order intake stood at HK$910.1 million with active ongoing tendering activities and many of the tenders submitted in the period due for determination in phases later this year. Segment revenue increased by 17.2% year-on-year or HK$123.2 million. - A number of projects, including a landmark engineering contract to reprovision critical sewage treatment works to caverns, were prioritised for commencement and execution. - New term contracts for sewage and E&M systems were also added to the recurrent operation, maintenance, and facility management services provided by the segment. - By deploying AI and Digital Twin under our industry-recognised AlgoWater® brand, the segment continued to strengthen our industry leading position by advancing in intelligent automation, predictive asset management, and real-time process optimisation that significantly enhance treatment efficiency and energy savings for industrial operations. - Continued to pursue project opportunities with partners in the Chinese Mainland and different parts in Asia and Europe. Information, Communications and Building Technologies (“ICBT”) - Segment revenue amounted to HK$290.9 million. Contracts-in-hand totalled HK$830.8 million. Order intake was HK$269.9 million. - As an early mover backed by its own R&D capability and extensive project experience, this segment was well positioned to continue to advance innovation. A robust digital foundation was established through the Digital Plant and Centralised Management Platform (CMP) that enables real-time insights and data-driven decisions. - Integration of IoT and advanced Building Management System (BMS) under our acclaimed DigiFusion® AI Smart Building Platform delivers optimised operational efficiency and enhanced tenant experiences in smart buildings and city infrastructure, as well as resource circularity for our clients. Lifts and Escalators - Revenue and contracts-in-hand were at HK$255.9 million and HK$657.7 million respectively. - Order intake totalled HK$278.4 million, with ongoing tendering activities in different parts of the world. - Transel Elevator & Electric Inc. (TEI), the associate company in the United States, maintained its strength as one of the largest independent lift and escalator companies in New York and continued to expand in the southeastern part of the country, strengthening our market positioning and future growth. - Competitiveness was strengthened with enhanced automation in production lines and strict quality controls, to anchor the end-to-end business model from design, through manufacturing, to installation and maintenance services. - The product portfolio was broadened in line with the expanding international market reach and enhanced with next-generation product innovations. For further details of the 2026 Interim Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited. About Analogue Holdings Limited Established in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators. The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (Shanghai Stock Code: 603912), specialises in precision environmental control technologies and related energy-saving and temperature control equipment for data centres.
  3. FinanceFosun International Delivers 160.3% YoY Profit Growth in 1H2026Companies: Fosun International LimitedOn the evening of 27 August, Fosun International announced its 2026 interim results. During the Reporting Period, its total revenue reached RMB86.96 billion; profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; overseas revenue reached RMB49.16 billion, with its share of total revenue rising to 56.5%; total debt to total capital ratio decreased to 55.7%. These figures show that Fosun’s results fall in the upper-middle range of the Company’s profit alert (profit attributable to owners of the parent is expected to range from approximately RMB1.5 billion to RMB1.8 billion, representing a year-on-year increase of approximately 127% to 172%) issued on 29 July. This marks Fosun’s return to a growth trajectory following the completion of a systematic realignment of “repairing the roof on a sunny day”. Over the past few years, Fosun has taken a rather unconventional path. Since 2022, in response to the severe market disruption caused by the pandemic, the Company has advanced its business streamlining and core business-focused strategy, divesting assets and businesses and generating cumulative cash proceeds of approximately RMB75 billion. In March 2026, pursuant to the principle of prudence, Fosun made one-off, non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments. The move drew considerable market attention at the time. At the Company’s 2025 annual results presentation at the end of March, Guo Guangchang, Chairman of Fosun International, explained, “This is about ‘repairing the roof on a sunny day’, allowing Fosun to focus its resources and efforts more effectively on core, high-growth areas.” The market has now responded to Fosun’s “repairing the roof on a sunny day” initiative. From the announcement of profit alert in early March to 25 August, before its interim results announcement, Fosun’s share price rose sharply from HKD3.6 to HKD5.41, representing an increase of more than 50%. The market has gradually recognized and priced in the Group’s “risk clearance” efforts. More importantly, the earnings growth driven by the Group’s businesses has begun to materialize. At the 2026 interim results presentation held in Hong Kong on 28 August, Guo Guangchang said: “The strong results recovery we delivered in the first half of the year reflects the outcome of the strategic adjustments we have made over the past few years. Our ‘repairing the roof on a sunny day’ strategy has paid off, allowing us to put historical burdens behind us. These results mark the beginning of Fosun’s continued progress along a trajectory of steady growth.” Solid Core Businesses, with Pharmaceuticals and Insurance Posting Strong Results First, let us look at Fosun’s core businesses. In the first half of 2026, its four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment — generated a total revenue of RMB63.88 billion, accounting for 73.5% of the Group’s total revenue, further demonstrating the results of its core business-focused strategy. Among them, the pharmaceutical and insurance segments delivered particularly strong performance. In the first half of the year, Fosun Pharma achieved operating revenue of RMB20.377 billion. Revenue from innovative drugs recorded a year-on-year increase of 13.84%, with their contribution to pharmaceutical business revenue rising to 33.35%, establishing innovative drugs as a key growth driver. Its innovative biopharmaceutical platform, Henlius, reported revenue of RMB3.5882 billion, representing a year-on-year increase of 27.3%, while net profit amounted to RMB430.4 million, up 10.3% year-on-year, sustaining growth momentum in revenue and profit. Commercialization of innovative drugs continued to gain traction. During the Reporting Period, Fosun Pharma had a total of 20 indications of 7 innovative drugs approved for launch both domestically and overseas. With their revenue share on a steady rise, innovative drugs have become the main growth engine driving the pharmaceutical business forward. The insurance segment delivered a stellar performance, with Fosun’s domestic and overseas insurance companies all posting broad-based improvements. Fidelidade’s overall market share in Portugal reached 30.1%, and its international business accounted for 26.7% of its consolidated total business. In the first half of the year, Fidelidade recorded net profit attributable to owners of the parent of EUR165 million, up 23.8% year-on-year, maintaining steady growth. In Chinese mainland, Pramerica Fosun Life Insurance recorded gross written premiums of RMB8.38 billion in the first half of 2026, up 52.2% year-on-year. Net profit reached RMB780 million, representing a year-on-year increase of 270% and exceeding its net profit for the full year of 2025. Fosun United Health Insurance reported a 36.2% year-on-year increase in revenue and net profit of RMB572 million. Peak Reinsurance’s reinsurance revenue and gross written premiums increased by 25% and 11.8% year-on- year, respectively, while net profit after tax reached USD89.70 million. In April 2026, Moody’s upgraded Peak Re’s rating from Baa1 to A3, with a “stable” outlook. Guo Guangchang said at the results presentation: “Integrating our insurance business with industries in which we have established competitive advantages has been a strategic priority for Fosun for over three decades — a critical linkage we have long sought to unlock. I believe we have now achieved it. This integration will significantly strengthen our industrial operational capabilities and future profitability, providing sustained momentum for Fosun’s development.” “Successfully navigating another cycle” is how the market has described Fosun’s latest round of adjustments. A closer look reveals how Fosun has successfully navigated the cycle. On the one hand, the Group has continued to streamline its business to generate cash proceeds. In the first half of the year, the Group generated proceeds equivalent to more than RMB12.0 billion from the divestment of non-strategic and non-core assets. Its total debt to total capital ratio was reduced to 55.7%, while its cash, bank balances and term deposits amounted to RMB61.214 billion. On the other hand, the innovation and globalization strategy that the Group has been pursuing for years has entered a value-realization phase, serving as the core engine driving profit recovery. Integrated Innovation Strategy Bears Fruit Since innovative drugs took off in the domestic market in 2025, Fosun has repeatedly broken into the spotlight, with multiple innovative drug business development (BD) drawing significant market attention. In fact, as the saying goes, “One minute on stage takes ten years of hard work off stage”. This series of innovation achievements is the result of Fosun’s forward-looking innovation strategy established nearly two decades ago. Notably, for more than a decade, Fosun has built a globally integrated innovation system across its core business areas, combining “independent R&D + investment incubation + ecosystem collaboration”, and has consistently made substantial investments in technology innovation. In the first half of this year alone, investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. In the first half of this year, Fosun saw a series of innovations come to fruition. HANSIZHUANG, independently developed by Henlius, received approval from the National Medical Products Administration (NMPA) for its perioperative indication in gastric cancer, pioneering a postoperative “chemo-sparing” regimen and making it the world’s first and only anti-PD-1 monoclonal antibody approved for this indication. Its core pipeline asset, HLX43, as a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC, has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC), with over 1,500 patients enrolled globally. To date, Henlius has 10 products approved in over 60 countries and regions, and has benefited over 1.1 million patients. In addition, FUMAINING (luvoxmetinib tablets), independently developed by Fosun Pharma, was approved for the treatment of paediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), continuing to fill the gap in the treatment of rare diseases. In terms of neurodegenerative diseases, Fosun Pharma expanded its global collaboration with AriBio on AR1001, extending its rights to develop and commercialize the product to key markets including the U.S., Europe and Japan. Meanwhile, post-marketing confirmatory clinical trials for sodium oligomannate capsules have progressed steadily, with more than 1,000 patients enrolled as of 31 July 2026. In addition, HT001, an oral NLRP3 inhibitor for the treatment of Parkinson’s disease in-licensed by Hengtai Bio, an investee and incubated company of Fosun Pharma, commenced its Phase I clinical trial in Australia. Fosun’s innovation achievements demonstrate the forward-looking nature of its innovation strategy and its ability to identify the right opportunities in R&D. As Guo Guangchang remarked at the results presentation, through years of effort, Fosun has built globally integrated innovation capabilities rooted in China. This distinctive strength of Fosun is expected to create greater value for all in the years ahead. “Fosun has never pursued innovation behind closed doors. Instead, we leverage our resource-integration capabilities and a global perspective to drive smart innovation, bringing together the best technologies, teams and supply chains from around the world to solve real problems. This is how we unlock vast market potential,” said Guo Guangchang. Unlocking Value through Global Operations Globalization has been another forward-looking strategic move for Fosun. Since its listing in Hong Kong in 2007, when many Chinese companies were still focused primarily on their domestic markets, Fosun had already begun expanding overseas ahead of its peers. Nearly two decades later, as a growing number of Chinese companies embrace the view that they must go global or risk being left behind, and seek to capture overseas markets by taking their products overseas, Fosun has already established a profound business presence in more than 40 countries and regions. With local teams operating overseas, it has successfully operated a number of companies within the Fosun ecosystem. “Global operations” have become a defining feature of Fosun’s globalization strategy and a core engine underpinning the development of its businesses. Guo Guangchang said at the interim results presentation that Fosun continues to strengthen its global operational capabilities. On the one hand, it is helping Chinese products and services enter overseas markets. On the other hand, it is introducing high-quality products and services from around the world into China. Drawing on the global resource-mobilization capabilities it has built over the years, Fosun is able to identify high-quality projects and technologies worldwide and rapidly mobilize the resources needed to advance them. In the first half of 2026, Fosun’s overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue, up 3 percentage points as compared to the same period of 2025 and marking a record high in the proportion of overseas revenue. In the field of pharmaceuticals and healthcare, Fosun made substantial progress in the global expansion of innovative drugs and commercial business development. Henlius’ HANSIZHUANG was approved for three new indications in the European Union (EU), while HLX11 (pertuzumab injection) was approved in the EU and HLX14 (denosumab injection) was approved in Canada. At the beginning of 2026, Fosun Pharma entered into a strategic partnership with Eisai for HANSIZHUANG, with an aggregate potential consideration exceeding USD300 million, underscoring how the global value of Chinese innovative drugs is being repriced by international markets. In the first half of the year, Yuyuan generated revenue of RMB532 million in Hong Kong SAR and Macau SAR in the first half of 2026, representing a year-on-year increase of 285.83%, while revenue from the Japanese market reached RMB306 million, representing a year-on-year increase of 6.09%. Laomiao has 15 stores in Hong Kong SAR, Macau SAR, overseas markets and duty-free channels. Club Med has also continued to expand its global footprint, with Club Med Urban Oasis Hangzhou Longwu already open and Club Med South Africa Beach & Safari now in soft opening. Leveraging Fosun’s global ecosystem, Fidelidade in the insurance segment has expanded its business from Portugal to Portuguese-speaking countries and markets across Europe, Latin America, and Africa. Its international business now accounts for 26.7% of its consolidated total business, with continued growth in Portuguese-speaking countries. Meanwhile, Peak Reinsurance has maintained steady growth thanks to its global business footprint. The guiding principle behind Fosun’s globalization strategy is “Combining Global Resources with China’s Capabilities”, deeply integrating China’s manufacturing capabilities, service capabilities, and innovation dividends, with global markets. Starting with leveraging China’s growth momentum to establish its business presence, and progressing to a two-way engagement of “mutual empowerment between China and the world”, Fosun has now entered the 3.0 phase of “global organization + local operations”. In this phase, Fosun “truly operates with a global perspective”, having developed the ability to foster cross-regional, cross-cultural, and cross-organizational synergies within its business ecosystem and support the continued growth of its overseas revenue. At the interim results presentation held on 28 August, Guo Guangchang said: “Fosun’s future development goal is to ‘spur the horse to full speed’. We have already positioned ourselves on a trajectory of steady growth. Going forward, we will continue to advance innovation-driven and global development in industries where we have established competitive advantages, building on our momentum and accelerating further.”
  4. FinanceGlobal Pumps Market Research Report 2026-2031 Now Available — Published as Atlas Copco Deepens Hygienic Pump Push with Pomac BV AcquisitionThe global pumps market was valued at USD 65 billion in 2025 and is projected to reach USD 88.36 billion by 2031, growing at a 5.25% CAGR. Market growth is driven by energy-efficient smart pumps, water and wastewater infrastructure, construction, industrial expansion, and building renovations. APAC leads with over 40% market share, while electric and centrifugal pumps dominate their segments. Multistage pumps are forecast to grow fastest. Key pump market players include Grundfos, Xylem, Flowserve, KSB, Sulzer, Ebara, and Wilo.
  5. FinanceFosun International Delivers 160.3% YoY Profit Growth in 1H2026Companies: Fosun International LimitedOn the evening of 27 August, Fosun International announced its 2026 interim results. During the Reporting Period, its total revenue reached RMB86.96 billion; profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; overseas revenue reached RMB49.16 billion, with its share of total revenue rising to 56.5%; total debt to total capital ratio decreased to 55.7%. These figures show that Fosun’s results fall in the upper-middle range of the Company’s profit alert (profit attributable to owners of the parent is expected to range from approximately RMB1.5 billion to RMB1.8 billion, representing a year-on-year increase of approximately 127% to 172%) issued on 29 July. This marks Fosun’s return to a growth trajectory following the completion of a systematic realignment of “repairing the roof on a sunny day”. Over the past few years, Fosun has taken a rather unconventional path. Since 2022, in response to the severe market disruption caused by the pandemic, the Company has advanced its business streamlining and core business-focused strategy, divesting assets and businesses and generating cumulative cash proceeds of approximately RMB75 billion. In March 2026, pursuant to the principle of prudence, Fosun made one-off, non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments. The move drew considerable market attention at the time. At the Company’s 2025 annual results presentation at the end of March, Guo Guangchang, Chairman of Fosun International, explained, “This is about ‘repairing the roof on a sunny day’, allowing Fosun to focus its resources and efforts more effectively on core, high-growth areas.” The market has now responded to Fosun’s “repairing the roof on a sunny day” initiative. From the announcement of profit alert in early March to 25 August, before its interim results announcement, Fosun’s share price rose sharply from HKD3.6 to HKD5.41, representing an increase of more than 50%. The market has gradually recognized and priced in the Group’s “risk clearance” efforts. More importantly, the earnings growth driven by the Group’s businesses has begun to materialize. At the 2026 interim results presentation held in Hong Kong on 28 August, Guo Guangchang said: “The strong results recovery we delivered in the first half of the year reflects the outcome of the strategic adjustments we have made over the past few years. Our ‘repairing the roof on a sunny day’ strategy has paid off, allowing us to put historical burdens behind us. These results mark the beginning of Fosun’s continued progress along a trajectory of steady growth.” Solid Core Businesses, with Pharmaceuticals and Insurance Posting Strong Results First, let us look at Fosun’s core businesses. In the first half of 2026, its four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment — generated a total revenue of RMB63.88 billion, accounting for 73.5% of the Group’s total revenue, further demonstrating the results of its core business-focused strategy. Among them, the pharmaceutical and insurance segments delivered particularly strong performance. In the first half of the year, Fosun Pharma achieved operating revenue of RMB20.377 billion. Revenue from innovative drugs recorded a year-on-year increase of 13.84%, with their contribution to pharmaceutical business revenue rising to 33.35%, establishing innovative drugs as a key growth driver. Its innovative biopharmaceutical platform, Henlius, reported revenue of RMB3.5882 billion, representing a year-on-year increase of 27.3%, while net profit amounted to RMB430.4 million, up 10.3% year-on-year, sustaining growth momentum in revenue and profit. Commercialization of innovative drugs continued to gain traction. During the Reporting Period, Fosun Pharma had a total of 20 indications of 7 innovative drugs approved for launch both domestically and overseas. With their revenue share on a steady rise, innovative drugs have become the main growth engine driving the pharmaceutical business forward. The insurance segment delivered a stellar performance, with Fosun’s domestic and overseas insurance companies all posting broad-based improvements. Fidelidade’s overall market share in Portugal reached 30.1%, and its international business accounted for 26.7% of its consolidated total business. In the first half of the year, Fidelidade recorded net profit attributable to owners of the parent of EUR165 million, up 23.8% year-on-year, maintaining steady growth. In Chinese mainland, Pramerica Fosun Life Insurance recorded gross written premiums of RMB8.38 billion in the first half of 2026, up 52.2% year-on-year. Net profit reached RMB780 million, representing a year-on-year increase of 270% and exceeding its net profit for the full year of 2025. Fosun United Health Insurance reported a 36.2% year-on-year increase in revenue and net profit of RMB572 million. Peak Reinsurance’s reinsurance revenue and gross written premiums increased by 25% and 11.8% year-on- year, respectively, while net profit after tax reached USD89.70 million. In April 2026, Moody’s upgraded Peak Re’s rating from Baa1 to A3, with a “stable” outlook. Guo Guangchang said at the results presentation: “Integrating our insurance business with industries in which we have established competitive advantages has been a strategic priority for Fosun for over three decades — a critical linkage we have long sought to unlock. I believe we have now achieved it. This integration will significantly strengthen our industrial operational capabilities and future profitability, providing sustained momentum for Fosun’s development.” “Successfully navigating another cycle” is how the market has described Fosun’s latest round of adjustments. A closer look reveals how Fosun has successfully navigated the cycle. On the one hand, the Group has continued to streamline its business to generate cash proceeds. In the first half of the year, the Group generated proceeds equivalent to more than RMB12.0 billion from the divestment of non-strategic and non-core assets. Its total debt to total capital ratio was reduced to 55.7%, while its cash, bank balances and term deposits amounted to RMB61.214 billion. On the other hand, the innovation and globalization strategy that the Group has been pursuing for years has entered a value-realization phase, serving as the core engine driving profit recovery. Integrated Innovation Strategy Bears Fruit Since innovative drugs took off in the domestic market in 2025, Fosun has repeatedly broken into the spotlight, with multiple innovative drug business development (BD) drawing significant market attention. In fact, as the saying goes, “One minute on stage takes ten years of hard work off stage”. This series of innovation achievements is the result of Fosun’s forward-looking innovation strategy established nearly two decades ago. Notably, for more than a decade, Fosun has built a globally integrated innovation system across its core business areas, combining “independent R&D + investment incubation + ecosystem collaboration”, and has consistently made substantial investments in technology innovation. In the first half of this year alone, investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. In the first half of this year, Fosun saw a series of innovations come to fruition. HANSIZHUANG, independently developed by Henlius, received approval from the National Medical Products Administration (NMPA) for its perioperative indication in gastric cancer, pioneering a postoperative “chemo-sparing” regimen and making it the world’s first and only anti-PD-1 monoclonal antibody approved for this indication. Its core pipeline asset, HLX43, as a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC, has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC), with over 1,500 patients enrolled globally. To date, Henlius has 10 products approved in over 60 countries and regions, and has benefited over 1.1 million patients. In addition, FUMAINING (luvoxmetinib tablets), independently developed by Fosun Pharma, was approved for the treatment of paediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), continuing to fill the gap in the treatment of rare diseases. In terms of neurodegenerative diseases, Fosun Pharma expanded its global collaboration with AriBio on AR1001, extending its rights to develop and commercialize the product to key markets including the U.S., Europe and Japan. Meanwhile, post-marketing confirmatory clinical trials for sodium oligomannate capsules have progressed steadily, with more than 1,000 patients enrolled as of 31 July 2026. In addition, HT001, an oral NLRP3 inhibitor for the treatment of Parkinson’s disease in-licensed by Hengtai Bio, an investee and incubated company of Fosun Pharma, commenced its Phase I clinical trial in Australia. Fosun’s innovation achievements demonstrate the forward-looking nature of its innovation strategy and its ability to identify the right opportunities in R&D. As Guo Guangchang remarked at the results presentation, through years of effort, Fosun has built globally integrated innovation capabilities rooted in China. This distinctive strength of Fosun is expected to create greater value for all in the years ahead. “Fosun has never pursued innovation behind closed doors. Instead, we leverage our resource-integration capabilities and a global perspective to drive smart innovation, bringing together the best technologies, teams and supply chains from around the world to solve real problems. This is how we unlock vast market potential,” said Guo Guangchang. Unlocking Value through Global Operations Globalization has been another forward-looking strategic move for Fosun. Since its listing in Hong Kong in 2007, when many Chinese companies were still focused primarily on their domestic markets, Fosun had already begun expanding overseas ahead of its peers. Nearly two decades later, as a growing number of Chinese companies embrace the view that they must go global or risk being left behind, and seek to capture overseas markets by taking their products overseas, Fosun has already established a profound business presence in more than 40 countries and regions. With local teams operating overseas, it has successfully operated a number of companies within the Fosun ecosystem. “Global operations” have become a defining feature of Fosun’s globalization strategy and a core engine underpinning the development of its businesses. Guo Guangchang said at the interim results presentation that Fosun continues to strengthen its global operational capabilities. On the one hand, it is helping Chinese products and services enter overseas markets. On the other hand, it is introducing high-quality products and services from around the world into China. Drawing on the global resource-mobilization capabilities it has built over the years, Fosun is able to identify high-quality projects and technologies worldwide and rapidly mobilize the resources needed to advance them. In the first half of 2026, Fosun’s overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue, up 3 percentage points as compared to the same period of 2025 and marking a record high in the proportion of overseas revenue. In the field of pharmaceuticals and healthcare, Fosun made substantial progress in the global expansion of innovative drugs and commercial business development. Henlius’ HANSIZHUANG was approved for three new indications in the European Union (EU), while HLX11 (pertuzumab injection) was approved in the EU and HLX14 (denosumab injection) was approved in Canada. At the beginning of 2026, Fosun Pharma entered into a strategic partnership with Eisai for HANSIZHUANG, with an aggregate potential consideration exceeding USD300 million, underscoring how the global value of Chinese innovative drugs is being repriced by international markets. In the first half of the year, Yuyuan generated revenue of RMB532 million in Hong Kong SAR and Macau SAR in the first half of 2026, representing a year-on-year increase of 285.83%, while revenue from the Japanese market reached RMB306 million, representing a year-on-year increase of 6.09%. Laomiao has 15 stores in Hong Kong SAR, Macau SAR, overseas markets and duty-free channels. Club Med has also continued to expand its global footprint, with Club Med Urban Oasis Hangzhou Longwu already open and Club Med South Africa Beach & Safari now in soft opening. Leveraging Fosun’s global ecosystem, Fidelidade in the insurance segment has expanded its business from Portugal to Portuguese-speaking countries and markets across Europe, Latin America, and Africa. Its international business now accounts for 26.7% of its consolidated total business, with continued growth in Portuguese-speaking countries. Meanwhile, Peak Reinsurance has maintained steady growth thanks to its global business footprint. The guiding principle behind Fosun’s globalization strategy is “Combining Global Resources with China’s Capabilities”, deeply integrating China’s manufacturing capabilities, service capabilities, and innovation dividends, with global markets. Starting with leveraging China’s growth momentum to establish its business presence, and progressing to a two-way engagement of “mutual empowerment between China and the world”, Fosun has now entered the 3.0 phase of “global organization + local operations”. In this phase, Fosun “truly operates with a global perspective”, having developed the ability to foster cross-regional, cross-cultural, and cross-organizational synergies within its business ecosystem and support the continued growth of its overseas revenue. At the interim results presentation held on 28 August, Guo Guangchang said: “Fosun’s future development goal is to ‘spur the horse to full speed’. We have already positioned ourselves on a trajectory of steady growth. Going forward, we will continue to advance innovation-driven and global development in industries where we have established competitive advantages, building on our momentum and accelerating further.”
  6. FinanceModern Dental Group Announces 2026 Interim ResultsRESULTS HIGHLIGHTS: - The Revenue for the six months ended 30 June 2026 was approximately HK$2,032.5 million, representing an increase of approximately 10.8% as compared to the same period in 2025. The growth in revenue was primarily attributable to the continued organic growth of the Group—driven by the accelerating adoption of digitalization across the global dental industry, particularly in Europe and Australia—alongside the stabilization and operational turnaround of the Mainland China market. This expansion was partially offset by a revenue decline in North America, which was impacted by a softer macroeconomic environment affecting high-value discretionary procedures, as well as management’s strategic decision to rationalize loss-making Dental Service Organization (DSO) accounts to optimize customer mix and protect margins. - The Gross Profit Margin for the six months ended 30 June 2026 was approximately 58.1%; the gross profit was approximately HK$1,180.9 million, reflecting an increase of approximately 17.4% as compared to the same period in 2025. - The Group’s EBITDA for the six months ended 30 June 2026 was approximately HK$ 560.7 million, representing an increase of approximately 22.8% as compared to the same period in 2025. - The Group’s Net Profit for the six months ended 30 June 2026 was approximately HK$ 377.6 million, representing an increase of 30.8% as compared to the same period in 2025. - Basic earnings per share for the six months ended 30 June 2026 amounted to HK40.07 cents, representing an increase of approximately 31.9% as compared to the same period in 2025. - The Board declared an interim dividend of HK14.0 cents per ordinary share for the six months ended 30 June 2026. ADDITIONAL HIGHLIGHTS: - For the six months ended 30 June 2026, the Group’s digital solution cases that are produced from its Mainland China, Thailand and Vietnam production facilities increased to approximately 627,773 cases, reflecting an increase of 29.2% as compared with the same period in 2025 as a result of our clients’ continued adoption of intra-oral scanners. HONG KONG, August 28, 2026 - 27 August 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, is pleased to announce the unaudited interim results for the six months ended 30 June, 2026 (“the Period”). In the first half of 2026, the global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalise on opportunities across regions. The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our well performance, the Group is well placed to sustain momentum and further strengthen its market leadership. Digitalisation remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–43% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivers superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years. European Businesses During the period under review, the European market recorded a revenue of approximately HK$1,093.3 million, representing an increase of approximately HK$173.0 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 53.8% of the Group’s total revenue. The increase of revenue from the European market was attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows. North American Businesses During the period under review, the North American market recorded a revenue of approximately HK$331.3 million, representing a decrease of approximately HK$34.4 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 16.3% of the Group’s total revenue. The top-line contraction in North America was primarily driven by a softer macroeconomic environment, which temporarily weighed on consumer sentiment and demand for high-value discretionary cosmetic procedures. In response, management proactively initiated a strategic rationalization of loss-making Dental Service Organization (DSO) accounts aimed at optimizing the customer mix, protecting gross margins, and focusing resources on higher-margin accounts. Concurrently, the Group’s diversified production footprint across the US, China, Vietnam, and Thailand continues to afford significant supply chain agility to navigate trade and tariff complexities—a key differentiator in the market. Demonstrating the resilience of this strategy, our US import business unit delivered a 1.4% period-on-period sales growth in the first half of 2026. This performance underscores how the accelerating trend toward clinical digitalization and the cost-competitiveness of our imported product lines have effectively mitigated and offset the impact of US tariffs. Greater China Businesses During the period under review, the Greater China market recorded a revenue of approximately HK$300.0 million, representing an increase of approximately HK$6.8 million as compared with six months ended 30 June 2025. This geographic market accounted for approximately 14.8% of the Group’s total revenue. Regional performance reflected diverging market dynamics across territories. In local currency terms, sales in Mainland China increased by approximately 0.9% year-on-year, signalling that the market has largely bottomed out from the initial impact of Volume-Based Procurement (VBP) policies and prolonged price competition. To protect sustainable profitability, the Group deliberately pivoted away from low-margin segments to focus on serving mid- to high-value customers. Conversely, sales in the Hong Kong market decreased by approximately 8.5% in local currency year-on-year. This contraction was primarily driven by a temporary reduction in local patient visits, as cross-border dental consumption increased due to aggressive promotions for dental treatments offered by Mainland China clinics targeting Hong Kong residents. Despite these near-term shifts, the Group remains optimistic about the mid- to long-term outlook for the Greater China region. Government procurement measures in Mainland China are expected to standardize prosthetic pricing and enhance market transparency, creating a more level playing field where the Group’s leading brand reputation, production scale, and operational efficiency serve as distinct competitive advantages. To capture evolving market demand, the Group is actively expanding its product portfolio, particularly in mid-end offerings and products. Australian Businesses During the period under review, the Australian market recorded a revenue of approximately HK$162.8 million, representing an increase of approximately HK$24.9 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 8.0% of the Group’s total revenue. The increase in revenue from Australia was primarily driven by strong adoption of digital dental products and anti-snoring devices, and wins in dental service organization (DSO) customers. Other Markets Other markets primarily include Indian Ocean countries, Malaysia, Taiwan, Singapore and Thailand. For the six months ended 30 June 2026, these markets recorded a revenue of approximately HK$145.2 million, representing an increase of approximately HK$27.4 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 7.1% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the strong revenue contributions from Thailand, Singapore and Malaysia. The scaled manufacturing hubs in Thailand and Vietnam have enhanced regional supply efficiency, broadened product availability, and strengthened the Group’s competitive footprint in the region. Future Prospects and Strategies Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry. With the Board’s extensive experience and prudent governance, the Group is well positioned to seize new business opportunities while remaining strict financial discipline to safeguard Shareholders’ interests. The Board expresses its sincere gratitude to our dedicated employees, loyal customers, suppliers, and business partners for their unwavering commitment. Their collective efforts have been instrumental in delivering another year of record results and will continue to support the Group’s long-term success. About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 30 countries and serve over 35,000 customers.
  7. IndustrialJelly Force Male Enhancement Gummies Label Guide: 82 mg Proprietary Blend, Supplement Facts Panel, and 60-Day Guarantee Terms for 2026Jelly Force Male Enhancement Gummies discloses its formula, Supplement Facts panel, GMP manufacturing, and 60-day guarantee terms.
  8. FinanceYork Space SystemsYork Space Systems to Present at Jefferies Global Industrials ConferenceDENVER, August 27, 2026--York Space Systems (York) (NYSE: YSS), today announced that Dirk Wallinger, CEO, will present at the 2026 Jefferies Global Industrials Conference in New York. During the course of this event, York may disclose material developments affecting its business and/or financial performance. Listeners may access the event via live audio webcast at ir.yorkspacesystems.com.
  9. FinanceElement Solutions IncElement Solutions Announces Mutual Termination of Merger Agreement with Solstice Advanced MaterialsMIAMI, August 27, 2026--Element Solutions Inc (NYSE: ESI) ("Element Solutions" or the "Company"), a global and diversified specialty chemicals technology company, today announced that the merger agreement between Element Solutions and Solstice Advanced Materials Inc. ("Solstice") has been mutually terminated.
  10. FinanceForgent Power Solutions, Inc.Forgent Power Solutions, Inc. to Report Fiscal Fourth Quarter and Full Year 2026 ResultsDAYTON, Minn., August 27, 2026--Forgent Power Solutions, Inc. (NYSE: FPS), a leading designer and manufacturer of electrical distribution equipment used in data centers, the power grid and energy-intensive industrial facilities, will report financial results for its fiscal fourth quarter and full year ended June 30, 2026, before the market opens on September 15, 2026, and management will host a conference call at 11:00 a.m. ET to discuss the results.
  11. FinanceAeroVironment, Inc.AV to Present at the 2026 Jefferies Global Industrials ConferenceARLINGTON, Va., August 27, 2026--AeroVironment, Inc. ("AV") (NASDAQ: AVAV) will participate in the upcoming 2026 Jefferies Global Industrials Conference in New York City, New York. AV Chairman, President and Chief Executive Officer Wahid Nawabi and Executive Vice President and Chief Financial Officer Sean Woodward will participate in a fireside chat on September 10 at 12:50 p.m.
  12. HealthcareOryon Cell TherapiesOryon Cell Therapies Appoints Kenny Choi, Ph.D. as Chief Technical OfficerWATERTOWN, Mass., August 27, 2026--Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced the appointment of Kenny Choi, Ph.D., as Chief Technical Officer (CTO). Dr. Choi will lead Oryon’s technical operations and Chemistry, Manufacturing, and Controls (CMC) strategy, including transfer of the manufacturing process for the company’s autologo